Precision medicine involves the same diagnosis for multiple patients but completely different treatments for each of them. There’s no “average” response for every patient. Many individual differences come alive in this process. These include genetics, biomarkers, environment, lifestyle, and other health information. It can influence disease prevention, diagnosis, and treatment decisions.
Recently, several other technologies like companion diagnostics, pharmacogenomics, multi-omics, artificial intelligence (AI), real-world data, and biomarker-driven clinical trials have emerged. They are shaping up to become a much larger ecosystem in precision medicine.
This guide looks into things driving it in 2026, companies shaping the field, and the landscape of the next generation of targeted drug development.
Understanding Precision Medicine
Precision medicine is an approach to preventing disease, diagnosing, and offering treatments by considering differences among people. It doesn’t assume that the same intervention will work equally well for everyone. Those differences can include the following for a person:
- Genetic and genomic profile
- Biomarkers
- Molecular characteristics of a disease
- Environment and lifestyle
- Previous treatment response
- Other clinical and health information.
Genomics is an important part of precision medicine, but the two terms shouldn’t be treated as synonyms. Modern precision medicine increasingly connects genomic + molecular + clinical + environmental + lifestyle information for a more precise understanding of a patient or patient subgroup.
Reasons It Is Gaining Momentum
The year-long discussions have changed the growing ability to actually collect, analyze, and apply enormous amounts of biological and clinical information in this field. There are several developments mentioned below that are moving the field forward:
Better Genomic and Molecular Profiling
Next-generation sequencing (NGS) and other molecular technologies can recognize genomic alterations and biomarkers. In oncology, this has helped shift parts of treatment selection. It has now upgraded from where a cancer originated to also considering what molecular alterations are driving it.
Biomarker-Driven Drug Development
As per the FDA, biomarkers are objectively measured characteristics. They can indicate health, disease, or response to an intervention. They can be helpful in detecting responses in patients, evaluating safety, monitoring treatment effects, and supporting precision medicine development.
Companion Diagnostics
Some targeted therapies depend on a test that sees whether a patient possesses the molecular characteristic needed to use that treatment safely and effectively. That’s why it becomes important for a drug development strategy.
Pharmacogenomics
Genetic variation can impact people’s metabolism or response to medicines. Pharmacogenomics seeks to use that information so it can improve treatment or dosing decisions where proper evidence is available.
Data at Scale
The following datasets can be studied well:
- Electronic health records
- Genomic databases
- Real-world evidence
- Large research programs
- Molecular information
- Artificial Intelligence
These tools can help researchers in analyzing complicated datasets. They do so by recognizing patterns across genomic, molecular, imaging, and clinical information.
Technologies Powering Precision Medicine in 2026
Several technologies work together and convert biological differences into clinically valuable information. These are given in the table below:
| Technology | Role in Precision Medicine |
| Genomics & NGS |
Detect genetic variants and molecular alterations associated with disease or treatment response
|
| Biomarkers |
Help identify disease subtypes, treatment-responsive populations, and therapeutic effects
|
| Companion Diagnostics |
Determine whether a patient may be eligible for a corresponding therapy
|
| Pharmacogenomics |
Examines relationships between genetic variation and drug response
|
| Multi-Omics |
Combines genomics with areas such as transcriptomics, proteomics, and metabolomics
|
| AI & Data Analytics |
Helps process and identify patterns across complex biological and clinical datasets
|
Important: These technologies rarely work in isolation. A genomic alteration may become a biomarker, and the biomarker may define a clinical trial population. A companion diagnostic may be developed to target it, and a targeted therapy may at last be approved for patients having tumors with such an alteration.
Key Players in Precision Medicine
Today’s ecosystem connects pharma, biotechnology, diagnostics, sequencing, AI, data science, academic research, and healthcare. Check the explanations below:
Pharma & Biotechnology Companies
Major pharmaceutical companies continue to advance biomarker-driven therapeutics, targeted oncology products, cell therapies, and other approaches in which biological characteristics help define treatment.
Not every drug using one of these modalities automatically qualifies as precision medicine. The defining feature is generally the ability to connect biological or molecular characteristics to a defined treatment strategy.
Companies developing precision medicine approaches increasingly work across the following modalities:
- Small-molecule targeted therapies
- Antibody-drug conjugates
- Bispecific antibodies
- Cell therapies
- Gene-targeted treatments
- Radioligand therapies
Mentioned below are some of these companies:
1. Roche
- Worldwide leader in biotechnology and pharmaceuticals
- A strong focus on oncology
- Portfolio includes targeted therapies and companion diagnostics
- Enables personalized treatment plans for cancer patients
2. Novartis
- At the forefront of oncology and gene therapy-like areas
- CAR-T cell therapy, Kymriah, is a groundbreaking treatment for certain types of blood cancer
- Showcases the potential of personalized therapies
3. Pfizer
- Developing targeted treatments across various therapeutic areas
- Collaboration with companies specializing in genomics and bioinformatics
- Enhance their capabilities in identifying patient-specific therapies
4. AstraZeneca
- Known for its work in oncology
- Innovative treatments are Tagrisso for non-small cell lung cancer and Lynparza for ovarian cancer
- Exemplary commitment to developing targeted therapies based on genetic and biomarker information
5. Bristol-Myers Squibb
- Specializes in immuno-oncology and precision medicine treatments
- Amazing work in cancer immunotherapy
- Drugs like Opdivo and Yervoy
- Highlights their dedication to advancing personalized ways
- Use the body’s immune system to fight cancer
6. Regeneron Pharmaceuticals
- A biotechnology company that invents, develops and commercializes medicines for serious diseases
- Uses large-scale human genetics research through the Regeneron Genetics Center to support target discovery and drug development
- Develops medicines across areas including oncology, hematology, rare diseases, immunology and neurology
- Its research capabilities span biologics, bispecific antibodies, genetic medicines and other therapeutic approaches
- Human genetic and molecular insights can help identify potential therapeutic targets and support more targeted treatment development
Diagnostic & Genomic Companies
Companies working in molecular diagnostics and genomic profiling are equally important. That’s because precision treatment depends on accurately identifying the relevant patient. This relationship between the drug and the diagnostic has become particularly important in precision oncology.
Their role can span:
Sequencing → Biomarker detection → Genomic profiling → Assay development → Companion diagnostics → Patient stratification
Let’s have a look at these leading companies:
1. Illumina
- A leading company in the field of genomics
- Provides sequencing technologies fundamental to precision medicine
- Platforms enable the identification of genetic mutations and biomarkers
- Critical for personalized treatment plans
2. Foundation Medicine
- Specializes in comprehensive genomic profiling
- Offers insights into the genetic alterations driving a patient’s cancer
- Their tests help oncologists choose the most effective therapy for their patients
3. Qiagen
- Provides sample and assay technologies for molecular diagnostics, applied testing, and pharmaceutical research
- Products & services help extract, clean, and assess DNA, RNA & proteins
- Supports the development of precision medicine applications
4. Thermo Fisher Scientific
- Offers a wide range of products and services for precision medicine
- Includes genetic sequencing tools
- Comprehensive portfolio supports research and clinical applications
- Enables the identification of genetic markers and the development of targeted therapies
5. Myriad Genetics
- Specializes in molecular diagnostic tests
- Particularly in cancer and other hereditary conditions
- Tests like BRACAnalysis for hereditary breast and ovarian cancer
- Provide critical information for personalized treatment plans and risk assessment
AI, Data & Health Technology Companies
Companies working with clinical and molecular datasets can help researchers identify patterns that would be difficult to extract manually. However, computational prediction and clinical validation are not the same thing. An AI-generated association still needs appropriate evidence before it can be relied upon for regulated clinical decision-making.
AI and advanced analytics are being explored for areas including the following:
- Biomarker discovery
- Patient stratification
- Genomic interpretation
- Medical imaging
- Drug discovery
- Trial design
- Real-world evidence
- Prediction of disease progression or treatment response
The list of these companies includes the following:
1. Google Health
- Subsidiary, Verily Life Sciences, invests in precision medicine
- Combines data analytics, genomics, and ML
- Advances personalized healthcare and crafts targeted therapies
2. Flatiron Health
- A healthcare technology company that uses real-world evidence to advance cancer research and treatment
- Aggregates and analyzes clinical data from cancer patients
- Provides insights for proper treatment strategies and outcomes
3. Tempus
- Leverages AI for at-scale data collection and analysis
- Aides in personalized treatment strategies
- Comprehensive data platform
- Integrates genomic sequencing data with clinical details
- Helps clinicians make data-backed decisions for their patients
4. GRAIL
- Focuses on early cancer detection using advanced sequencing technology and data science
- Identifies cancer at its earliest stages
- Boosts the chances of successful treatment and patient survival
Companion Diagnostics in Precision Medicine
Companion diagnostics (CDx) are an important part of precision medicine because they can help identify whether a patient has the biological characteristic relevant to a particular therapy. The FDA defines a companion diagnostic as a medical device, often an in vitro diagnostic, that provides information essential for the safe and effective use of a corresponding therapeutic product.
Depending on the therapeutic context, a companion diagnostic may help identify:
- Patients most likely to benefit from a treatment
- Patients at increased risk of serious adverse reactions
- Patients whose treatment response may need to be monitored
A practical example is the FDA approval of inavolisib (Itovebi) with palbociclib and fulvestrant for certain patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. FoundationOne® Liquid CDx was also approved as a companion diagnostic to help identify eligible patients.
The precision medicine pathway can therefore involve:
Patient → Molecular or Biomarker Test → Relevant Alteration Identified → Treatment Eligibility → Targeted Therapy
The FDA maintains an updated list of authorized companion diagnostic devices, reflecting the growing integration of diagnostic testing and therapeutic development.
Selected Precision Medicine Drug Pipeline 2026
Drug development pipelines change frequently as candidates advance, generate new clinical data, enter regulatory review, or are discontinued. The examples below represent selected precision medicine-related programs publicly listed by companies or recently reported through official company updates as of August 2026. They are not an exhaustive list of the global pipeline.
| Company Name | Pipeline Candidate/Programme & Approach | Indication & Development Stage |
| AstraZeneca | Saruparib through PARP-1 Selective Targeted Therapy |
|
| AstraZeneca | Sonesitatug vedotin via CLDN18.2-targeted ADC |
|
| AstraZeneca | Zadavotide guraxetan through PSMA-targeted radioconjugate |
|
| Pfizer | PF-08032560 using KAT6/7 inhibitor in biomarker-selected disease |
|
| Merck+Moderna | Intismeran autogene (V940/mRNA-4157) via Individualized neoantigen therapy designed around a patient’s tumor mutations |
|
| Novartis | Lutathera additional development program through SSTR-targeted radioligand therapy |
|
| Regeneron | Nezastomig combinations through PSMA-targeted bispecific approach |
|
| Regeneron | Ubamatamab via MUC16-directed bispecific approach |
|
Key Precision Medicine Development Trends
Now, let’s look at the therapeutic and technological directions shaping precision drug development below:
1. Biomarker-Driven Oncology
Cancer remains one of the most developed applications of precision medicine. Molecular characteristics like the following can influence treatment strategies in specific cancers and indications:
- EGFR
- HER2
- BRCA
- PIK3CA
Other actionable alterations
This is also changing clinical development. Instead of enrolling every patient with a particular tumor type, some studies enrich their populations using biomarkers to identify patients more likely to respond.
The FDA also places importance on these in modern drug development:
- Biomarkers
- Subgroup identification
- Enrichment designs
- Tissue-agnostic trials
2. Antibody-Drug Conjugates (ADC)
It combines a targeting antibody with a therapeutic payload. The aim is to recognize a particular target expressed by cancer cells and deliver the payload more selectively. The precision element becomes particularly relevant where target expression or another biomarker influences patient selection and treatment strategy.
3. Bispecific Antibodies
These interact with two different targets or epitopes. Some bispecific approaches in oncology bind a cancer-associated target while also engaging an immune-cell target. This helps direct an immune response toward cancer cells.
Biomarker selection, disease biology, and patient stratification can help determine the place of greatest benefit.
4. Genetically Targeted Therapies & Rare Diseases
Rare diseases are associated with specific genetic abnormalities. This makes molecular diagnosis especially important for defining disease subtypes and developing targeted approaches.
The FDA’s Division of Translational and Precision Medicine specifically identifies rare diseases and genetically targeted therapies. It includes RNA-directed oligonucleotides. Future therapies may target a specific gene, mutation, pathway, or molecular mechanism instead of developing a treatment for a wide disease label.
5. Tissue-Agnostic Treatment
One of the most interesting changes created by precision oncology is the concept of treating a cancer according to its molecular characteristics rather than only its tissue of origin. Tissue-agnostic development asks whether a particular molecular feature can predict treatment response across different tumor types.
The FDA has already identified tissue-agnostic trials and approvals as part of the evolution of precision drug development. This represents a fundamental change in thinking—sometimes what a tumor is molecularly can matter alongside where it started anatomically.
Conclusion
Development today increasingly asks, “For whom does the treatment work? Why does it work? And how can we identify those patients trustworthily?
Answering those questions can connect everything mentioned in the blog. All of it fits within a single development program. That also means the regulatory pathway can become more interconnected.
Artixio supports pharmaceutical, biotech, and MedTech companies with regulatory intelligence, development strategy, product registration, technical and medical writing, regulatory submissions, and lifecycle compliance across global markets. Talk to Artixio at info@artixio.com about building a global regulatory pathway around it.
FAQs
How does pharmacogenomics support precision medicine?
Pharmacogenomics studies relationships between genomic variation and medication response. Where clinically supported, genotype information can help inform therapeutic strategy, dosage, likelihood of benefit, or risk of toxicity.
How is AI used in precision medicine?
AI and machine learning can help analyze complex genomic, molecular, imaging, and clinical datasets. Potential applications include biomarker discovery, patient stratification, drug development, and prediction. However, clinical use still requires appropriate validation and regulatory consideration.
What is the difference between precision medicine and personalized medicine?
These are interchangeable terms. Precision medicine generally emphasizes using genomic, environmental, lifestyle, and other information. It aims to identify more precise prevention, diagnostic, or treatment approaches for individuals or defined patient groups. It doesn’t necessarily mean manufacturing a unique medicine for every individual.
